Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

TARG-SUP

Financiado

Targeting TGF activation likely the core mechanism of immunosuppression by hu...

Targeting TGF activation likely the core mechanism of immunosuppression by human regulatory T cells. Regulatory T lymphocytes (Tregs) inhibit immune responses and are required to maintain immune tolerance. Tregs express membrane protein GARP, which displays latent TGF-β1 on the cell surface. Immunosuppression by human Tregs appea... ver más

31/03/2021

UCLouvain

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITE CATHOLIQUE DE LOUVAIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-03-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-CoG-2015: ERC Consolidator Grant

I+D

Cerrada hace 9 años

0% 100% 100%

2 Participantes

UCLouvain

1.99M€ | Lider

CERAMICA DECORATIVA SA EN LI...

Proyectos interesantes

SAF2016-80803-R ANALISIS DE UNA NUEVA FUNCION DE P21 COMO SUPPRESOR SELECTIV... 145K€ Cerrado

RYC-2016-21155 miRNA control of immune tolerance, tumor immunology and auto... 309K€ Cerrado

BES-2014-070272 EL METABOLISMO DEL DIACILGLICEROL EN LA REGULACION DE LA TOL... 88K€ Cerrado

SAF2010-15060 BLOQUEO DE LOS MECANISMOS DE INMUNOSUPRESION PARA AUMENTAR L... 121K€ Cerrado

SAF2017-89437-P INMUNOTERAPIA DE TUMORES SOLIDOS CON CELULAS T SECRETORAS DE... 157K€ Cerrado

PID2021-128206NB-I00 MODELANDO LA CARCINOGENESIS CON CELULAS PLUTIPOTENTES PARA E... 200K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 60 meses Fecha Inicio: 2016-03-21
Fecha Fin: 2021-03-31

Líder del proyecto

UNIVERSITE CATHOLIQUE DE LOUVAIN

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Regulatory T lymphocytes (Tregs) inhibit immune responses and are required to maintain immune tolerance. Tregs express membrane protein GARP, which displays latent TGF-β1 on the cell surface. Immunosuppression by human Tregs appears to require GARP-mediated activation of TGF-β1. My objectives are to unravel the molecular aspects of TGF-β1 activation by GARP and determine the functional importance of this process in physiological and pathological conditions where Tregs or other GARP-expressing cells are present. As this implies the development of new tools to modulate GARP-dependent TGF-β1 activation and Treg immunosuppression, we will also explore their potential for the treatment of immune-related human diseases, and notably cancer. More specifically, I will: - Derive antibodies that modulate GARP-mediated TGF-β1 production by human Tregs and perform structural analyses in the presence of these antibodies to identify tri-dimensional changes in GARP/TGF-β1 complexes that lead to the release of active TGF-β1. - Identify and characterize additional proteins implicated in TGF-β1 activation by human Tregs, as GARP is required but not sufficient for TGF-β1 activation by Tregs. - Determine the immunological and clinical impact of inhibitory anti-GARP mAbs on cancer in mice. We will derive anti-murine GARP mAbs. As an alternative, we will generate mutant mice expressing a chimeric mouse/human GARP that is recognized by anti-human GARP mAbs. The antibodies will be tested in tumour-bearing mice treated or not with other immunotherapies including vaccines or immunostimulatory antibodies. - Determine whether blocking anti-GARP mAbs improve immune responses to microbial vaccines or to chronic infections, as these represent important applications for transient inhibition of Treg activity in humans. - Analyse the expression and roles of GARP in non-Treg cells to better understand GARP functions, which remain largely unknown, and predict potential toxicities of anti-GARP mAbs.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores